Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H22N2O.C4H6O4 |
Molecular Weight | 388.4574 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2
InChI
InChIKey=KBAUFVUYFNWQFM-UHFFFAOYSA-N
InChI=1S/C17H22N2O.C4H6O4/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16;5-3(6)1-2-4(7)8/h4-12H,13-14H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
Molecular Formula | C4H6O4 |
Molecular Weight | 118.088 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C17H22N2O |
Molecular Weight | 270.3694 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.drugbank.ca/drugs/DB00366Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/cdi/doxylamine.html
Sources: http://www.drugbank.ca/drugs/DB00366
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/cdi/doxylamine.html
Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic. Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects. Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.
CNS Activity
Sources: http://www.rxmedscanada.com/doxylamine-aldex.php
Curator's Comment: Penetrating into the central nervous system, the drug has a marked sedative effect, promoting sleep.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://pubmed.ncbi.nlm.nih.gov/23357028/ |
42.0 nM [Ki] | ||
Target ID: CHEMBL2094109 Sources: https://pubmed.ncbi.nlm.nih.gov/23357028/ |
200.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unisom Approved UseAllergic rhinitis or other respiratory allergies (oral liquid only): Temporary relief of rhinorrhea, sneezing, itchy nose or throat, and itchy, watery eyes due to hay fever or other respiratory allergies
Insomnia (tablets only): Reduce difficulty falling asleep Launch Date1978 |
|||
Sources: https://www.drugs.com/cdi/doxylamine.html |
Primary | Unisom Approved UseAllergic rhinitis or other respiratory allergies (oral liquid only): Temporary relief of rhinorrhea, sneezing, itchy nose or throat, and itchy, watery eyes due to hay fever or other respiratory allergies
Insomnia (tablets only): Reduce difficulty falling asleep Launch Date1978 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
6.3 mg single, nasal dose: 6.3 mg route of administration: Nasal experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
27.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
12.7 mg single, nasal dose: 12.7 mg route of administration: Nasal experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
142 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
3.2 mg single, nasal dose: 3.2 mg route of administration: Nasal experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
124.91 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
61.94 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/ |
12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
99 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4056080/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
83.3 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIDOXINE HYDROCHLORIDE |
DOXYLAMINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
168.6 ng/mL |
40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: PYRIDOXINE HYDROCHLORIDE |
DOXYLAMINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
117.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
6.3 mg single, nasal dose: 6.3 mg route of administration: Nasal experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
161.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
12.7 mg single, nasal dose: 12.7 mg route of administration: Nasal experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
751.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
81.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
3.2 mg single, nasal dose: 3.2 mg route of administration: Nasal experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1697.58 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
859.74 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/ |
12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1280.9 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIDOXINE HYDROCHLORIDE |
DOXYLAMINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
3721.5 ng × h/mL |
40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: PYRIDOXINE HYDROCHLORIDE |
DOXYLAMINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
6.3 mg single, nasal dose: 6.3 mg route of administration: Nasal experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
12.7 mg single, nasal dose: 12.7 mg route of administration: Nasal experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29671128/ |
3.2 mg single, nasal dose: 3.2 mg route of administration: Nasal experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23633146/ |
12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4056080/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXYLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10.1 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: PYRIDOXINE HYDROCHLORIDE |
DOXYLAMINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
11.9 h |
40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: PYRIDOXINE HYDROCHLORIDE |
DOXYLAMINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
150 mg single, oral Overdose Dose: 150 mg Route: oral Route: single Dose: 150 mg Sources: Page: p.179 |
unknown, 2 n = 1 Health Status: unknown Age Group: 2 Sex: M Population Size: 1 Sources: Page: p.179 |
Other AEs: Agitation, Dilated pupils... |
25 mg single, oral Studied dose Dose: 25 mg Route: oral Route: single Dose: 25 mg Sources: Page: p.133 |
healthy, 28 - 58 n = 12 Health Status: healthy Age Group: 28 - 58 Sex: M+F Population Size: 12 Sources: Page: p.133 |
Other AEs: Somnolence... |
12.7 mg single, intranasal Highest studied dose Dose: 12.7 mg Route: intranasal Route: single Dose: 12.7 mg Sources: Page: p.133 |
unhealthy, 35.9 (8.00) n = 24 Health Status: unhealthy Condition: Chronic intermittent sleep impairment Age Group: 35.9 (8.00) Sex: M+F Population Size: 24 Sources: Page: p.133 |
|
13 mg/kg single, oral Overdose Dose: 13 mg/kg Route: oral Route: single Dose: 13 mg/kg Sources: Page: p.1 |
unknown |
Other AEs: Rhabdomyolysis... |
20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral; 1-2/day) Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Nausea and vomiting of pregnancy Sources: Page: p.1 |
Other AEs: Somnolence... Other AEs: Somnolence Sources: Page: p.1 |
20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral; 1-2/day) Sources: Page: p.3CNS depressants |
unhealthy Health Status: unhealthy Condition: Nausea and vomiting of pregnancy Sources: Page: p.3 |
Other AEs: Drowsiness... Other AEs: Drowsiness (grade 3) Sources: Page: p.3 |
20 mg single, oral Recommended Dose: 20 mg Route: oral Route: single Dose: 20 mg Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: Page: p.48 |
healthy n = 48 Health Status: healthy Sex: F Population Size: 48 Sources: Page: p.48 |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting Sources: Page: p.48 |
20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: Page: p.63 |
healthy n = 37 Health Status: healthy Sex: F Population Size: 37 Sources: Page: p.63 |
Disc. AE: Vomiting, Decreased hemoglobin... AEs leading to discontinuation/dose reduction: Vomiting Sources: Page: p.63Decreased hemoglobin Visual impairment |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | 150 mg single, oral Overdose Dose: 150 mg Route: oral Route: single Dose: 150 mg Sources: Page: p.179 |
unknown, 2 n = 1 Health Status: unknown Age Group: 2 Sex: M Population Size: 1 Sources: Page: p.179 |
|
Dilated pupils | 150 mg single, oral Overdose Dose: 150 mg Route: oral Route: single Dose: 150 mg Sources: Page: p.179 |
unknown, 2 n = 1 Health Status: unknown Age Group: 2 Sex: M Population Size: 1 Sources: Page: p.179 |
|
Somnolence | 50% | 25 mg single, oral Studied dose Dose: 25 mg Route: oral Route: single Dose: 25 mg Sources: Page: p.133 |
healthy, 28 - 58 n = 12 Health Status: healthy Age Group: 28 - 58 Sex: M+F Population Size: 12 Sources: Page: p.133 |
Rhabdomyolysis | 13 mg/kg single, oral Overdose Dose: 13 mg/kg Route: oral Route: single Dose: 13 mg/kg Sources: Page: p.1 |
unknown |
|
Somnolence | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral; 1-2/day) Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Nausea and vomiting of pregnancy Sources: Page: p.1 |
|
Drowsiness | grade 3 | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral; 1-2/day) Sources: Page: p.3CNS depressants |
unhealthy Health Status: unhealthy Condition: Nausea and vomiting of pregnancy Sources: Page: p.3 |
Vomiting | Disc. AE | 20 mg single, oral Recommended Dose: 20 mg Route: oral Route: single Dose: 20 mg Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: Page: p.48 |
healthy n = 48 Health Status: healthy Sex: F Population Size: 48 Sources: Page: p.48 |
Decreased hemoglobin | Disc. AE | 20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: Page: p.63 |
healthy n = 37 Health Status: healthy Sex: F Population Size: 37 Sources: Page: p.63 |
Visual impairment | Disc. AE | 20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: Page: p.63 |
healthy n = 37 Health Status: healthy Sex: F Population Size: 37 Sources: Page: p.63 |
Vomiting | Disc. AE | 20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Co-administed with:: pyridoxine hydrochloride(20 mg oral single dose) Sources: Page: p.63 |
healthy n = 37 Health Status: healthy Sex: F Population Size: 37 Sources: Page: p.63 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8975784/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8975784/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8975784/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8975784/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8975784/ |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001 Apr |
|
The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. | 2001 Aug |
|
Nausea and vomiting of pregnancy. Evidence-based treatment algorithm. | 2002 Feb |
|
The use of CAM by women suffering from nausea and vomiting during pregnancy. | 2002 May 17 |
|
Differential protonation and dynamic structure of doxylamine succinate in solution using 1H and 13C NMR. | 2004 Jul |
|
Treatment of primary insomnia. | 2004 May-Jun |
|
Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. | 2004 Oct |
|
Effect of (+) or (-) camphorsulfonic acid additives to the mobile phase on enantioseparations of some basic drugs on a Chiralcel OD column. | 2005 Aug 12 |
|
[Transitory acute psychosis with serotoninergic syndrome at the time of an intoxication by dosulepin associated with doxylamine and ethanol]. | 2006 Nov-Dec |
|
Comparison of lactated Ringer's solution and 0.9% saline in the treatment of rhabdomyolysis induced by doxylamine intoxication. | 2007 Apr |
|
American Gastroenterological Association institute medical position statement on the use of gastrointestinal medication in pregnancy. | 2007 Feb |
|
First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. | 2007 May |
|
A thyrotoxicosis outbreak due to dietary pills in Paris. | 2008 Dec |
|
"DXemon juice:" analytical evaluation of an extraction process for the purification and freebasing of dextromethorphan from cold preparations. | 2008 Dec |
|
Simultaneous determination of a ternary mixture of doxylamine succinate, pyridoxine hydrochloride, and folic acid by the ratio spectra-zero-crossing, double divisor-ratio spectra derivative, and column high-performance liquid chromatographic methods. | 2008 Sep-Oct |
|
Doxylamine toxicity: seizure, rhabdomyolysis and false positive urine drug screen for methadone. | 2009 |
|
Does advice from pharmacy staff vary according to the nonprescription medicine requested? | 2009 Nov |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Authenticity of claims made in drug promotional literature. | 2010 Feb |
|
Managing hyperemesis gravidarum: a multimodal challenge. | 2010 Jul 15 |
|
[Hyperemesis gravidarum: a rare but potentially severe complication of the first trimester of pregnancy]. | 2010 Jun 20 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/cdi/doxylamine.html
Usual Adult Dose for Allergic Rhinitis
Doxylamine 5 mg oral tablet, chewable:
10 mg orally every 4 to 6 hours not to exceed 6 doses daily.
Usual Adult Dose for Allergic Conjunctivitis
Doxylamine 5 mg oral tablet, chewable:
10 mg orally every 4 to 6 hours not to exceed 6 doses daily.
Usual Adult Dose for Insomnia
12 years of age and older: 25 mg orally 30 minutes before bed
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7871531
Doxylamine at 50 ug/ml inhibited both differentiation and proliferation in rat embryo limb bud cell cultures
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:13 GMT 2023
by
admin
on
Fri Dec 15 15:01:13 GMT 2023
|
Record UNII |
V9BI9B5YI2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
||
|
CFR |
21 CFR 341.12
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
||
|
CFR |
21 CFR 522.784
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
74772
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
23665
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000087529
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
11224
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
562-10-7
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
C47501
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
209-228-7
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
m4759
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
1227006
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
V9BI9B5YI2
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
SUB01834MIG
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
DBSALT001402
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
C035385
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
V9BI9B5YI2
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL1004
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY | |||
|
DTXSID7020552
Created by
admin on Fri Dec 15 15:01:13 GMT 2023 , Edited by admin on Fri Dec 15 15:01:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|